Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).
| Website: | www.amgen.com |
| Email: | investor.relations@amgen.com |
| Main Phone: | +1 805 447-1000 |
| Address: | One Amgen Center Drive |
| Address 2: | Suite 2650 |
| State: | CA |
| City / Town: | Thousand Oaks |
| Country: | USA |
| Postal Code: | 91320-1799 |
| Exchange: | NGS |
| CEO: | Robert A. Bradway |
| Employees: | 21500 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Let's take a deep dive into sectors, the Fed and trade wars.
Omecamtiv mecarbil, a cardiac myosin activator, is being studied in heart failure with reduced ejection fraction (HFrEF)
Developing T cell engagers targeting prostate cancer, ovarian cancer, multiple myeloma and small cell lung cancer (Image: Harpoon Therapeutics)
The proposed deal for this biotechnology unicorn would be the largest US IPO in the industry (Image: Moderna)
The noise trader influence is only growing, as the rise of self-directed traders and the relentless noise of the financial press mean the noise to signal ratio is worse than ever.
Third major acquisition of an oncolytic virus company by Big Pharma this year (Image: UCLA Jonsson Comprehensive Cancer Center).
Lead candidate targeting wet age-related macular degeneration and diabetic retinopathy.
Engaging the body’s natural protein disposal system to treat cancers and other diseases (Image: Arvinas).
This article covers the highlights from the world of cancer investing, in particular, with the goal of helping you pick out the most important news of the week.
Approving new biosimilars is a top priority for the FDA (Image: Contract Pharma).
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).
| Website: | www.amgen.com |
| Email: | investor.relations@amgen.com |
| Main Phone: | +1 805 447-1000 |
| Address: | One Amgen Center Drive |
| Address 2: | Suite 2650 |
| State: | CA |
| City / Town: | Thousand Oaks |
| Country: | USA |
| Postal Code: | 91320-1799 |
| Exchange: | NGS |
| CEO: | Robert A. Bradway |
| Employees: | 21500 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Let's take a deep dive into sectors, the Fed and trade wars.
Omecamtiv mecarbil, a cardiac myosin activator, is being studied in heart failure with reduced ejection fraction (HFrEF)
Developing T cell engagers targeting prostate cancer, ovarian cancer, multiple myeloma and small cell lung cancer (Image: Harpoon Therapeutics)
The proposed deal for this biotechnology unicorn would be the largest US IPO in the industry (Image: Moderna)
The noise trader influence is only growing, as the rise of self-directed traders and the relentless noise of the financial press mean the noise to signal ratio is worse than ever.
Third major acquisition of an oncolytic virus company by Big Pharma this year (Image: UCLA Jonsson Comprehensive Cancer Center).
Lead candidate targeting wet age-related macular degeneration and diabetic retinopathy.
Engaging the body’s natural protein disposal system to treat cancers and other diseases (Image: Arvinas).
This article covers the highlights from the world of cancer investing, in particular, with the goal of helping you pick out the most important news of the week.
Approving new biosimilars is a top priority for the FDA (Image: Contract Pharma).
| Last Price 236.66 | Change $ -0.94 | Change % -0.40 | Tick N/A |
| Bid 236.65 | Bid Size 300.00 | Ask 236.68 | Ask Size 200.00 |
| Open 238.75 | High 239.70 | Low 235.76 | Prev Close 237.60 |
| Last Trade | Volume 998,956 | 52 Wk Hi 245.00 | 52 Wk Low 166.31 |
| Market Cap 140.6 bi | Ex-Div Date | Div Rate 6.40 | Yield 2.6940 |
| Shares 594,183,541.00 | EPS (TTM) 13.03 | PE Ratio 18.50 | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 45 | 74 |
| Number of Buys | 23 | 31 |
| Number of Sells | 22 | 43 |
| Net Activity | -8304 | 75103 |
| Last 10 Buys | Shares |
|---|---|
| Fred Hassan | 1,000 |
| Fred Hassan | 1,000 |
| Frank C. Herringer | 1,000 |
| Frank C. Herringer | 1,000 |
| Robert A. Bradway | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| Sean Harper | 1,000 |
| De Francois Carbonnel | 1,000 |
| Sean Harper | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 224 | 224 | 224 | 224 |
| Low Target Price Estimate | 165 | 165 | 165 | 165 |
| Mean Target Price Estimate | 193.94 | 193.94 | 193.12 | 193.94 |
| Standard Deviation | 15.01 | 15.01 | 14.92 | 15.01 |
| Date of Most Recent Estimate | 06/03/18 | 05/22/18 | 05/22/18 | 06/03/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| CT ORDER | 1 | 2018-05-30 | |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-05-22 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2018-05-22 |
| CT ORDER | 1 | 2018-05-17 | |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 12 | 13 | 14 | 14 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.22 | 2.26 | 2.3 | 2.3 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait